Meeting
2017 ASCO Annual Meeting
Clinical and molecular characterization of patients with metastatic colorectal cancer harbouring DNA mismatch repair deficiency.
Authors
Romain Cohen
Medical Oncology Department, Saint-Antoine Hospital, Paris, France
Romain Cohen , Elisabeth Hain , Pascale Cervera , Olivier Buhard , Sylvie Dumont , Armelle Bardier , Jean-Baptiste Bachet , Jean Marc Gornet , Sarah Dumont , Rachid Kaci , Philippe Bertheau , Florence Renaud , Frederic Bibeau , Alex Duval , Magali Svrcek , Thierry Andre , Yann Parc
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Citation
J Clin Oncol 35, 2017 (suppl; abstr 3563)
DOI
10.1200/JCO.2017.35.15_suppl.3563
Abstract #
3563
Poster Bd #
186
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
SEAMARK: Randomized phase 2 study of pembrolizumab + encorafenib + cetuximab vs pembrolizumab alone for first-line treatment of BRAF V600E–mutant microsatellite instability–high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC).
First Author: Scott Kopetz
Poster
2022 ASCO Annual Meeting
SEAMARK: Randomized phase 2 study of pembrolizumab + encorafenib + cetuximab versus pembrolizumab alone for first-line treatment of BRAF V600E-mutant and microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC).
First Author: Scott Kopetz
Poster
2021 ASCO Annual Meeting
Resectability, conversion and resections rates, and outcomes in RAS&BRAF wildtype (wt), RAS mutant (mt) and BRAFmt metastatic colorectal cancer (mCRC) subgroups in the prospective Finnish RAXO-study.
First Author: Pia J. Osterlund
Poster
2018 ASCO Annual Meeting
What is the prognostic impact of BRAF mutation in patients undergoing resection of colorectal liver metastases? Results of nationwide intergroup (ACHBT, FRENCH, AGEO) cohort of 249 patients.
First Author: Jean-Baptiste Bachet